pyridoxine has been researched along with Disease Models, Animal in 63 studies
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source
vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The moderately pyridoxine (vitamin B6)-deficient male rat was introduced by us as an animal model (B6DHT) for the study of hypertension." | 8.80 | Hypertension, calcium channel and pyridoxine (vitamin B6). ( Dakshinamurti, K; Ganguly, PK; Lal, KJ, 1998) |
| "Pyridoxine-dependent epilepsy (PDE) is a rare autosomal recessive disease caused by mutations in the ALDH7A1 gene leading to blockade of the lysine catabolism pathway." | 7.96 | A novel mouse model for pyridoxine-dependent epilepsy due to antiquitin deficiency. ( Al-Shekaili, HH; Bosma, M; Ciapaite, J; Friedman, JM; Horvath, G; Kema, IP; Leavitt, BR; Lengyell, TC; Pena, I; Petkau, TL; Ross, C; Simpson, EM; van Faassen, M; van Karnebeek, C; Verhoeven-Duif, NM, 2020) |
| "Theophylline-induced seizures have significant morbidity and mortality and are difficult to treat." | 7.69 | Pyridoxine as therapy in theophylline-induced seizures. ( Glenn, GM; Kelly, P; Krober, MS; McCarty, J; Weir, M, 1995) |
| " It is the most common inborn error of sulfur metabolism and is the cause of classical homocystinuria, a condition characterized by very high levels of plasma total homocysteine and methionine." | 4.95 | Cystathionine β-synthase deficiency: Of mice and men. ( Kruger, WD, 2017) |
| "The moderately pyridoxine (vitamin B6)-deficient male rat was introduced by us as an animal model (B6DHT) for the study of hypertension." | 4.80 | Hypertension, calcium channel and pyridoxine (vitamin B6). ( Dakshinamurti, K; Ganguly, PK; Lal, KJ, 1998) |
| "Pyridoxine-dependent epilepsy (PDE) is a rare autosomal recessive disease caused by mutations in the ALDH7A1 gene leading to blockade of the lysine catabolism pathway." | 3.96 | A novel mouse model for pyridoxine-dependent epilepsy due to antiquitin deficiency. ( Al-Shekaili, HH; Bosma, M; Ciapaite, J; Friedman, JM; Horvath, G; Kema, IP; Leavitt, BR; Lengyell, TC; Pena, I; Petkau, TL; Ross, C; Simpson, EM; van Faassen, M; van Karnebeek, C; Verhoeven-Duif, NM, 2020) |
| "Elevated concentrations of pipecolic acid have been reported in plasma and CSF of patients with pyridoxine-dependent epilepsy, but its molecular background is unclear." | 3.73 | Pipecolic acid concentrations in brain tissue of nutritionally pyridoxine-deficient rats. ( Hoeger, H; Jakobs, C; Leschnik, M; Muehl, A; Plecko, B; Stoeckler-Ipsiroglu, S; Stromberger, C; Struys, E, 2005) |
| "Using an atherogenic diet that produces both hyperhomocysteinemia and hypercholesterolemia, we tested the hypothesis that dietary supplementation with B vitamins (folic acid, vitamin B(12), and vitamin B(6)) would prevent hyperhomocysteinemia, vascular dysfunction, and atherosclerotic lesions in monkeys." | 3.71 | Supplementation of atherogenic diet with B vitamins does not prevent atherosclerosis or vascular dysfunction in monkeys. ( Heistad, DD; Lentz, SR; Malinow, MR; Piegors, DJ, 2001) |
| " The effects of systemic pretreatment with hydrocortisone (5-25 mg/kg), pyridoxine (20-250 mg/kg), and sodium valproate (VPA; 200 and 400 mg/kg) against the NMDA-induced automatisms, emprosthotonic (hyperflexion), and clonic-tonic seizures were determined." | 3.70 | Age-specific N-methyl-D-aspartate-induced seizures: perspectives for the West syndrome model. ( Kábová, R; Liptáková, S; Pometlová, M; Slamberová, R; Velísek, L, 1999) |
| "Theophylline-induced seizures have significant morbidity and mortality and are difficult to treat." | 3.69 | Pyridoxine as therapy in theophylline-induced seizures. ( Glenn, GM; Kelly, P; Krober, MS; McCarty, J; Weir, M, 1995) |
| "Typically, attention to peripheral neuropathies resulting from exposure to environmental agents is limited relative to more commonly diagnosed causes of peripheral neuropathy (diabetes and chemotherapeutic agents)." | 2.50 | Animal models of peripheral neuropathy due to environmental toxicants. ( Jortner, BS; Rao, DB; Sills, RC, 2014) |
| "Treatment with pyridoxine significantly improved the epileptic phenotype and extended lifespan in plpbp-/- animals." | 1.51 | PLPHP deficiency: clinical, genetic, biochemical, and mechanistic insights. ( Abdelrahim, RA; Al Futaisi, A; Al-Shekaili, HH; Al-Thihli, K; Arnold, GL; Ban, K; Begtrup, A; Boon, M; Bosma, M; Boycott, KM; Brimble, E; Bui, T; Cho, MT; Ciapaite, J; Demarest, S; Drögemöller, B; Dyment, DA; Ekker, M; Friedman, JM; Gerkes, EH; Haaxma, CA; Heiner-Fokkema, MR; Houten, SM; Ito, Y; Ivy, AS; Jans, J; Johnstone, DL; Kamsteeg, EJ; Kema, IP; Kernohan, KD; Koolen, DA; Kosuta, C; Koul, R; Lepage, N; Lines, MA; Majewski, J; McBride, S; Noble, S; Olson, H; Pena, IA; Ross, CJ; Roussel, Y; Sigurdardottir, LY; Tarailo-Graovac, M; van Faassen, M; van Karnebeek, CDM; van Roermund, CWT; Verhoeven-Duif, N; Violante, S; Wanders, RJA; Wasserman, WW; Wevers, RA; Wolf, NI, 2019) |
| "The sideroblastic anemias are a heterogeneous group of inherited and acquired disorders characterized by the presence of ring sideroblasts in the bone marrow." | 1.42 | Diagnosis and treatment of sideroblastic anemias: from defective heme synthesis to abnormal RNA splicing. ( Cazzola, M; Malcovati, L, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (26.98) | 18.7374 |
| 1990's | 7 (11.11) | 18.2507 |
| 2000's | 14 (22.22) | 29.6817 |
| 2010's | 18 (28.57) | 24.3611 |
| 2020's | 7 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, W | 1 |
| Yao, J | 1 |
| Pham, V | 1 |
| Whitney, T | 1 |
| Froese, D | 1 |
| Friesen, A | 1 |
| Stang, L | 1 |
| Xu, C | 1 |
| Shuaib, A | 1 |
| Diakur, JM | 1 |
| Haque, W | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Zheng, Y | 1 |
| Chen, ZY | 1 |
| Ma, WJ | 1 |
| Wang, QZ | 1 |
| Liang, H | 1 |
| Ma, AG | 1 |
| Uckun, FM | 1 |
| Saeed, M | 1 |
| Awili, M | 1 |
| Ozercan, IH | 1 |
| Qazi, S | 1 |
| Lee, C | 1 |
| Shibli, A | 1 |
| Skolnick, AW | 1 |
| Prusmack, A | 1 |
| Varon, J | 1 |
| Barrera, CI | 1 |
| Orhan, C | 1 |
| Volk, M | 1 |
| Sahin, K | 1 |
| Yun, S | 1 |
| Kim, W | 1 |
| Kang, MS | 1 |
| Kim, TH | 1 |
| Kim, Y | 1 |
| Ahn, JO | 1 |
| Choi, JH | 2 |
| Hwang, IK | 1 |
| Chung, JY | 2 |
| Huang, J | 1 |
| Yancey, PG | 1 |
| Tao, H | 1 |
| Borja, MS | 1 |
| Smith, LE | 1 |
| Kon, V | 1 |
| Davies, SS | 1 |
| Linton, MF | 1 |
| Payne, AM | 1 |
| Sawers, A | 1 |
| Allen, JL | 1 |
| Stapley, PJ | 1 |
| Macpherson, JM | 1 |
| Ting, LH | 1 |
| Al-Shekaili, HH | 2 |
| Petkau, TL | 1 |
| Pena, I | 1 |
| Lengyell, TC | 1 |
| Verhoeven-Duif, NM | 1 |
| Ciapaite, J | 2 |
| Bosma, M | 3 |
| van Faassen, M | 2 |
| Kema, IP | 2 |
| Horvath, G | 1 |
| Ross, C | 1 |
| Simpson, EM | 1 |
| Friedman, JM | 2 |
| van Karnebeek, C | 1 |
| Leavitt, BR | 1 |
| Kruger, WD | 1 |
| Pena, IA | 2 |
| Roussel, Y | 2 |
| Daniel, K | 1 |
| Mongeon, K | 1 |
| Johnstone, D | 1 |
| Weinschutz Mendes, H | 1 |
| Saxena, V | 1 |
| Lepage, N | 2 |
| Chakraborty, P | 1 |
| Dyment, DA | 2 |
| van Karnebeek, CDM | 2 |
| Verhoeven-Duif, N | 2 |
| Bui, TV | 1 |
| Boycott, KM | 2 |
| Ekker, M | 2 |
| MacKenzie, A | 1 |
| Evans, E | 1 |
| Piccio, L | 1 |
| Cross, AH | 1 |
| Merigliano, C | 1 |
| Mascolo, E | 1 |
| La Torre, M | 1 |
| Saggio, I | 1 |
| Vernì, F | 1 |
| Lyu, L | 1 |
| Wang, CL | 1 |
| Li, ZY | 1 |
| Shi, YJ | 1 |
| Zhang, YH | 1 |
| Mi, Y | 1 |
| Hu, Z | 1 |
| Johnstone, DL | 1 |
| Tarailo-Graovac, M | 1 |
| Wolf, NI | 1 |
| Ivy, AS | 1 |
| Demarest, S | 1 |
| van Roermund, CWT | 1 |
| Kernohan, KD | 1 |
| Kosuta, C | 1 |
| Ban, K | 1 |
| Ito, Y | 1 |
| McBride, S | 1 |
| Al-Thihli, K | 1 |
| Abdelrahim, RA | 1 |
| Koul, R | 1 |
| Al Futaisi, A | 1 |
| Haaxma, CA | 1 |
| Olson, H | 1 |
| Sigurdardottir, LY | 1 |
| Arnold, GL | 1 |
| Gerkes, EH | 1 |
| Boon, M | 1 |
| Heiner-Fokkema, MR | 1 |
| Noble, S | 1 |
| Jans, J | 1 |
| Koolen, DA | 1 |
| Kamsteeg, EJ | 1 |
| Drögemöller, B | 1 |
| Ross, CJ | 1 |
| Majewski, J | 1 |
| Cho, MT | 1 |
| Begtrup, A | 1 |
| Wasserman, WW | 1 |
| Bui, T | 1 |
| Brimble, E | 1 |
| Violante, S | 1 |
| Houten, SM | 1 |
| Wevers, RA | 1 |
| Lines, MA | 1 |
| Wanders, RJA | 1 |
| Rao, DB | 1 |
| Jortner, BS | 1 |
| Sills, RC | 1 |
| Gengenbacher, M | 1 |
| Vogelzang, A | 1 |
| Schuerer, S | 1 |
| Lazar, D | 1 |
| Kaiser, P | 1 |
| Kaufmann, SH | 1 |
| Mayengbam, S | 2 |
| Raposo, S | 2 |
| Aliani, M | 2 |
| House, JD | 2 |
| Kobayashi, D | 1 |
| Yoshimura, T | 1 |
| Johno, A | 1 |
| Ishikawa, M | 1 |
| Sasaki, K | 1 |
| Wada, K | 1 |
| Kobayashi, C | 2 |
| Kurohane, K | 2 |
| Imai, Y | 2 |
| Cazzola, M | 1 |
| Malcovati, L | 1 |
| Abdou, HM | 1 |
| Wahby, MM | 1 |
| Ollivier-Lanvin, K | 1 |
| Keeler, BE | 1 |
| Siegfried, R | 1 |
| Houlé, JD | 1 |
| Lemay, MA | 1 |
| Kuypers, NJ | 1 |
| Hoane, MR | 1 |
| Jones, DC | 1 |
| Alphey, MS | 1 |
| Wyllie, S | 1 |
| Fairlamb, AH | 1 |
| Muriel, P | 1 |
| Deheza, R | 1 |
| Perry, TA | 1 |
| Weerasuriya, A | 1 |
| Mouton, PR | 1 |
| Holloway, HW | 1 |
| Greig, NH | 1 |
| Plecko, B | 1 |
| Hoeger, H | 1 |
| Jakobs, C | 1 |
| Struys, E | 1 |
| Stromberger, C | 1 |
| Leschnik, M | 1 |
| Muehl, A | 1 |
| Stoeckler-Ipsiroglu, S | 1 |
| Shimada, D | 1 |
| Fukuda, A | 1 |
| Kawaguchi, H | 1 |
| Kato, N | 1 |
| Yoshida, H | 1 |
| Kanouchi, H | 1 |
| Oka, T | 1 |
| Bosnak, M | 1 |
| Ayyildiz, M | 1 |
| Yildirim, M | 1 |
| Agar, E | 1 |
| Kim, JE | 1 |
| Kim, DW | 1 |
| Kwak, SE | 1 |
| Kwon, OS | 1 |
| Choi, SY | 1 |
| Kang, TC | 1 |
| Hwang, CY | 1 |
| Youn, HY | 1 |
| Vorhees, CV | 1 |
| Butcher, RE | 1 |
| Berry, HK | 1 |
| Heisey, GB | 1 |
| Hughes, HC | 1 |
| Lang, CM | 1 |
| Rozmiarek, H | 1 |
| Arosio, B | 1 |
| Santambrogio, D | 1 |
| Gagliano, N | 1 |
| Annoni, G | 1 |
| Buckmaster, PS | 1 |
| Holliday, TA | 1 |
| Bai, SC | 1 |
| Rogers, QR | 1 |
| Glenn, GM | 1 |
| Krober, MS | 1 |
| Kelly, P | 1 |
| McCarty, J | 1 |
| Weir, M | 1 |
| Shah, RM | 1 |
| Izadnegahdar, MF | 1 |
| Hehn, BM | 1 |
| Young, AV | 1 |
| Dakshinamurti, K | 1 |
| Lal, KJ | 1 |
| Ganguly, PK | 1 |
| Kábová, R | 1 |
| Liptáková, S | 1 |
| Slamberová, R | 1 |
| Pometlová, M | 1 |
| Velísek, L | 1 |
| Vasdev, S | 1 |
| Wadhawan, S | 1 |
| Ford, CA | 1 |
| Parai, S | 1 |
| Longerich, L | 1 |
| Gadag, V | 1 |
| Lentz, SR | 1 |
| Piegors, DJ | 1 |
| Malinow, MR | 1 |
| Heistad, DD | 1 |
| Hofmann, MA | 1 |
| Lalla, E | 1 |
| Lu, Y | 1 |
| Gleason, MR | 1 |
| Wolf, BM | 1 |
| Tanji, N | 1 |
| Ferran, LJ | 1 |
| Kohl, B | 1 |
| Rao, V | 1 |
| Kisiel, W | 1 |
| Stern, DM | 1 |
| Schmidt, AM | 1 |
| Callizot, N | 1 |
| Warter, JM | 1 |
| Poindron, P | 1 |
| Dellon, AL | 1 |
| Dellon, ES | 1 |
| Tassler, PL | 1 |
| Ellefson, RD | 1 |
| Hendrickson, M | 1 |
| França, DS | 1 |
| Souza, AL | 1 |
| Almeida, KR | 1 |
| Dolabella, SS | 1 |
| Martinelli, C | 1 |
| Coelho, MM | 1 |
| Chattopadhyay, M | 1 |
| Wolfe, D | 1 |
| Huang, S | 1 |
| Goss, J | 1 |
| Glorioso, JC | 1 |
| Mata, M | 1 |
| Fink, DJ | 1 |
| Carey, RB | 1 |
| Brause, BD | 1 |
| Roberts, RB | 1 |
| Gross, S | 1 |
| Coleman, M | 1 |
| Randall, J | 1 |
| Chiba, S | 1 |
| Edamura, M | 1 |
| Ito, M | 1 |
| Kikuchi, S | 1 |
| Matsumoto, H | 1 |
| Pichkhadze, GM | 1 |
| Beaconsfield, P | 1 |
| Rainsbury, R | 1 |
| Ginsburg, J | 1 |
| Miyoshi, T | 1 |
| Goto, I | 1 |
| Zervas, NT | 1 |
| Hori, H | 1 |
| Rosoff, CB | 1 |
| Harker, LA | 1 |
| Slichter, SJ | 1 |
| Scott, CR | 1 |
| Ross, R | 1 |
| Ruiz-García, F | 1 |
| Rey de Viñas, JL | 1 |
| Lucas-Gallego, J | 1 |
| Börcsök, E | 1 |
| Földi, K | 1 |
| Wittlinger, G | 1 |
| Földi, M | 2 |
| Machill, G | 1 |
| Haufe, U | 1 |
| Haufe, F | 1 |
| Lubs, H | 1 |
| Külz, J | 1 |
| Rohmann, E | 1 |
| Smith, DB | 1 |
| Gallagher, BB | 1 |
| Davis, SD | 1 |
| Nelson, T | 1 |
| Shepard, TH | 1 |
| Zoltán, OT | 1 |
| Maurer, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1, Double-blind, Placebo-controlled, Randomized, Two-Part, Ascending Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Rejuveinix (RJX) in Healthy Participants[NCT03680105] | Phase 1 | 76 participants (Actual) | Interventional | 2018-08-24 | Completed | ||
| Adjuvant Effects of Vitamin A and Vitamin D Supplementation on Treatment of Children With ADHD:A Randomized, Double Blind, Placebo-controlled, Multicentric Trial.[NCT04284059] | Phase 4 | 504 participants (Anticipated) | Interventional | 2021-02-25 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants with abnormal and clinically significant findings based on ECG. (NCT03680105)
Timeframe: Up to Day 2 for Part 1 and Up to Day 8 for Part 2
| Intervention | Participants (Count of Participants) |
|---|---|
| Part 1; Placebo | 0 |
| Part 1; Cohort 1; RJX | 0 |
| Part 1; Cohort 2; RJX | 0 |
| Part 1; Cohort 3; RJX | 0 |
| Part 1; Cohort 4; RJX | 0 |
| Part 1; Cohort 5; RJX | 0 |
| Part 1; Cohort 6; RJX | 0 |
| Part 2; Placebo | 0 |
| Part 2; Cohort 1; RJX | 0 |
| Part 2; Cohort 2; RJX | 0 |
| Part 2; Cohort 3; RJX | 0 |
Number of participants with clinically significant values and actual changes from baseline of continuous neurological assessments. (NCT03680105)
Timeframe: Up to Day 5 for Part 1 and Up to Day 12 for Part 2
| Intervention | Participants (Count of Participants) |
|---|---|
| Part 1; Placebo | 0 |
| Part 1; Cohort 1; RJX | 0 |
| Part 1; Cohort 2; RJX | 0 |
| Part 1; Cohort 3; RJX | 0 |
| Part 1; Cohort 4; RJX | 0 |
| Part 1; Cohort 5; RJX | 0 |
| Part 1; Cohort 6; RJX | 0 |
| Part 2; Placebo | 0 |
| Part 2; Cohort 1; RJX | 0 |
| Part 2; Cohort 2; RJX | 1 |
| Part 2; Cohort 3; RJX | 0 |
Number of participants with indicated AEs receiving RJX as assessed by CTCAE v4 03 (NCT03680105)
Timeframe: Up to Day 5 for Part 1 and Up to Day 12 for Part 2
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mild TEAE72191553 | Mild TEAE72191554 | Mild TEAE72191555 | Mild TEAE72191556 | Mild TEAE72191557 | Mild TEAE72191558 | Mild TEAE72191559 | Mild TEAE72191560 | Mild TEAE72191562 | Mild TEAE72191563 | Mild TEAE72191561 | Moderate TEAE72191553 | Moderate TEAE72191554 | Moderate TEAE72191555 | Moderate TEAE72191556 | Moderate TEAE72191557 | Moderate TEAE72191558 | Moderate TEAE72191559 | Moderate TEAE72191560 | Moderate TEAE72191561 | Moderate TEAE72191562 | Moderate TEAE72191563 | Severe TEAE72191553 | Severe TEAE72191554 | Severe TEAE72191555 | Severe TEAE72191556 | Severe TEAE72191557 | Severe TEAE72191558 | Severe TEAE72191559 | Severe TEAE72191560 | Severe TEAE72191561 | Severe TEAE72191562 | Severe TEAE72191563 | Related TEAE72191553 | Related TEAE72191554 | Related TEAE72191555 | Related TEAE72191556 | Related TEAE72191558 | Related TEAE72191559 | Related TEAE72191560 | Related TEAE72191561 | Related TEAE72191562 | Related TEAE72191563 | Related TEAE72191557 | |||||||||||||||||||||||||||||||||||||||||||||
| Without TEAE | With TEAE | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Placebo | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Cohort 1; RJX | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Cohort 2; RJX | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Cohort 3; RJX | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Cohort 4; RJX | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Cohort 5; RJX | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Cohort 6; RJX | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 2; Placebo | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 2; Cohort 1; RJX | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 2; Cohort 2; RJX | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 2; Cohort 3; RJX | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Placebo | 11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Cohort 1; RJX | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Cohort 2; RJX | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Cohort 3; RJX | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Cohort 5; RJX | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Cohort 6; RJX | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 2; Placebo | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 2; Cohort 1; RJX | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 2; Cohort 3; RJX | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Placebo | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Cohort 1; RJX | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Cohort 4; RJX | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Cohort 5; RJX | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 2; Cohort 1; RJX | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 2; Cohort 2; RJX | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 2; Cohort 3; RJX | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Placebo | 13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Cohort 1; RJX | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Cohort 2; RJX | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Cohort 4; RJX | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Cohort 5; RJX | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 2; Cohort 1; RJX | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 2; Cohort 2; RJX | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 2; Cohort 3; RJX | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Cohort 2; RJX | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Cohort 4; RJX | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Cohort 5; RJX | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 2; Placebo | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Cohort 4; RJX | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Cohort 5; RJX | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 2; Placebo | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Cohort 2; RJX | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 2; Cohort 2; RJX | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 2; Cohort 3; RJX | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Cohort 2; RJX | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 1; Cohort 4; RJX | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 2; Cohort 2; RJX | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Part 2; Cohort 3; RJX | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
5 reviews available for pyridoxine and Disease Models, Animal
| Article | Year |
|---|---|
Cystathionine β-synthase deficiency: Of mice and men.
Topics: Animals; Animals, Newborn; Cystathionine beta-Synthase; Disease Models, Animal; Genotype; Homocystei | 2017 |
Use of Vitamins and Dietary Supplements by Patients With Multiple Sclerosis: A Review.
Topics: Acetylcarnitine; Animals; Ascorbic Acid; Biotin; Caffeine; Creatine; Curcumin; Dietary Supplements; | 2018 |
Animal models of peripheral neuropathy due to environmental toxicants.
Topics: Acrylamide; Animals; Carbon Disulfide; Disease Models, Animal; Hazardous Substances; Hexanes; Histol | 2014 |
Progress in experimental phenylketonuria: a critical review.
Topics: Abnormalities, Multiple; Animals; Disease Models, Animal; Energy Metabolism; Female; Fenclonine; Glu | 1981 |
Hypertension, calcium channel and pyridoxine (vitamin B6).
Topics: Animals; Calcium Channels; Disease Models, Animal; Hypertension; Pyridoxine; Vitamin B 6 Deficiency | 1998 |
58 other studies available for pyridoxine and Disease Models, Animal
| Article | Year |
|---|---|
Pyridoxine as a template for the design of antiplatelet agents.
Topics: Animals; Brain Ischemia; Disease Models, Animal; Humans; In Vitro Techniques; Intracranial Thrombosi | 2004 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
B Vitamins Supplementation Can Improve Cognitive Functions and May Relate to the Enhancement of Transketolase Activity in A Rat Model of Cognitive Impairment Associated with High-fat Diets.
Topics: Animals; Cognitive Dysfunction; Diet, High-Fat; Dietary Supplements; Disease Models, Animal; Folic A | 2021 |
Evaluation of the potential of Rejuveinix plus dexamethasone against sepsis.
Topics: Animals; Anti-Inflammatory Agents; Ascorbic Acid; COVID-19 Drug Treatment; Dexamethasone; Disease Mo | 2022 |
Neuropathological changes in dorsal root ganglia induced by pyridoxine in dogs.
Topics: Animals; Disease Models, Animal; Dogs; Ganglia, Spinal; H-Reflex; Neuroglia; Neurons; Peripheral Ner | 2020 |
Reactive Dicarbonyl Scavenging Effectively Reduces MPO-Mediated Oxidation of HDL and Restores PON1 Activity.
Topics: Animals; Anti-Inflammatory Agents; Apolipoprotein A-I; Aryldialkylphosphatase; ATP Binding Cassette | 2020 |
Reorganization of motor modules for standing reactive balance recovery following pyridoxine-induced large-fiber peripheral sensory neuropathy in cats.
Topics: Animals; Cats; Disease Models, Animal; Electromyography; Muscle, Skeletal; Nerve Fibers, Myelinated; | 2020 |
A novel mouse model for pyridoxine-dependent epilepsy due to antiquitin deficiency.
Topics: Aldehyde Dehydrogenase; Animals; Behavior, Animal; Disease Models, Animal; Epilepsy; Female; Lysine; | 2020 |
Pyridoxine-Dependent Epilepsy in Zebrafish Caused by Aldh7a1 Deficiency.
Topics: Aldehyde Dehydrogenase; Animals; Disease Models, Animal; Epilepsy; gamma-Aminobutyric Acid; Gene Kno | 2017 |
Protective role of vitamin B6 (PLP) against DNA damage in Drosophila models of type 2 diabetes.
Topics: Animals; Body Size; Brain; Chromosome Aberrations; Diabetes Mellitus, Experimental; Diabetes Mellitu | 2018 |
Serum Metabolic Profiling in a Mouse Model of Adriamycin-Induced Focal Segmental Glomerulosclerosis.
Topics: Animals; Body Weight; Computational Biology; Disease Models, Animal; Doxorubicin; Fatty Acids, Monou | 2018 |
PLPHP deficiency: clinical, genetic, biochemical, and mechanistic insights.
Topics: Animals; Disease Models, Animal; Epilepsy; Female; HEK293 Cells; Humans; Male; Phenotype; Proteins; | 2019 |
Dietary pyridoxine controls efficacy of vitamin B6-auxotrophic tuberculosis vaccine bacillus Calmette-Guérin ΔureC::hly Δpdx1 in mice.
Topics: Animals; BCG Vaccine; Dietary Supplements; Disease Models, Animal; Female; Genes, Bacterial; Immunit | 2014 |
Oral exposure to the anti-pyridoxine compound 1-amino D-proline further perturbs homocysteine metabolism through the transsulfuration pathway in moderately vitamin B₆ deficient rats.
Topics: Animals; Asymptomatic Diseases; Biomarkers; Cystathionine; Cystathionine gamma-Lyase; Diet; Disease | 2015 |
Decrease in pyridoxal-5'-phosphate concentration and increase in pyridoxal concentration in rat plasma by 4'-O-methylpyridoxine administration.
Topics: Animals; Brain; Disease Models, Animal; Foodborne Diseases; gamma-Aminobutyric Acid; Ginkgo biloba; | 2015 |
Lack of Impact of High Dietary Vitamin A on T Helper 2-Dependent Contact Hypersensitivity to Fluorescein Isothiocyanate in Mice.
Topics: Animals; Dermatitis, Contact; Diet; Dietary Supplements; Disease Models, Animal; Diterpenes; Fluores | 2015 |
A Vitamin B-6 Antagonist from Flaxseed Perturbs Amino Acid Metabolism in Moderately Vitamin B-6-Deficient Male Rats.
Topics: Amino Acids; Aminobutyrates; Animals; Cystathionine; Cystathionine beta-Synthase; Cystathionine gamm | 2016 |
Diagnosis and treatment of sideroblastic anemias: from defective heme synthesis to abnormal RNA splicing.
Topics: Alternative Splicing; Anemia, Refractory; Anemia, Sideroblastic; Animals; Disease Models, Animal; Er | 2015 |
Neuroprotection of Grape Seed Extract and Pyridoxine against Triton-Induced Neurotoxicity.
Topics: Animals; Antioxidants; Brain; Cytoprotection; Disease Models, Animal; DNA Fragmentation; Drug Therap | 2016 |
Proprioceptive neuropathy affects normalization of the H-reflex by exercise after spinal cord injury.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Electric Stimulation; Electromyography; Exerc | 2010 |
Pyridoxine administration improves behavioral and anatomical outcome after unilateral contusion injury in the rat.
Topics: Animals; Behavior, Animal; Brain Injuries; Disease Models, Animal; Functional Laterality; Male; Moto | 2010 |
High dose dietary pyridoxine induces T-helper type 1 polarization and decreases contact hypersensitivity response to fluorescein isothiocyanate in mice.
Topics: Animals; Cytokines; Dendritic Cells; Dermatitis, Contact; Diet; Disease Models, Animal; Female; Fluo | 2012 |
Chemical, genetic and structural assessment of pyridoxal kinase as a drug target in the African trypanosome.
Topics: Amino Acid Sequence; Animals; Antiprotozoal Agents; Disease Models, Animal; Enzyme Inhibitors; Gene | 2012 |
Fibrosis and glycogen stores depletion induced by prolonged biliary obstruction in the rat are ameliorated by metadoxine.
Topics: Administration, Oral; Alanine Transaminase; Alcohol Deterrents; Animals; Bilirubin; Cholestasis, Ext | 2003 |
Pyridoxine-induced toxicity in rats: a stereological quantification of the sensory neuropathy.
Topics: Animals; Cell Count; Cell Size; Disease Models, Animal; Disease Progression; Electrophysiology; Gang | 2004 |
Pipecolic acid concentrations in brain tissue of nutritionally pyridoxine-deficient rats.
Topics: Animal Nutritional Physiological Phenomena; Animals; Brain; Disease Models, Animal; Epilepsy; Female | 2005 |
Effect of high dose of pyridoxine on mammary tumorigenesis.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Disease Models, Animal; Dose-Response Relationship, | 2005 |
The role of nitric oxide in the anticonvulsant effects of pyridoxine on penicillin-induced epileptiform activity in rats.
Topics: Analysis of Variance; Animals; Anticonvulsants; Arginine; Disease Models, Animal; Dose-Response Rela | 2007 |
Potential role of pyridoxal-5'-phosphate phosphatase/chronopin in epilepsy.
Topics: Actin Cytoskeleton; Actin Depolymerizing Factors; Animals; Cloning, Molecular; Disease Models, Anima | 2008 |
Pyridoxine induced neuropathy by subcutaneous administration in dogs.
Topics: Animals; Body Weight; Disease Models, Animal; Dogs; Electrophysiology; Neurodegenerative Diseases; P | 2008 |
The guinea pig as a model for isoniazid-induced reactions.
Topics: Animals; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Disease Models, Animal | 1980 |
Changes in expression of the albumin, fibronectin and type I procollagen genes in CCl4-induced liver fibrosis: effect of pyridoxol L,2-pyrrolidon-5 carboxylate.
Topics: Albumins; Animals; Blotting, Northern; Carbon Tetrachloride; Disease Models, Animal; Drug Combinatio | 1993 |
Brainstem auditory evoked potential interwave intervals are prolonged in vitamin B-6-deficient cats.
Topics: Acoustic Stimulation; Animals; Body Weight; Cats; Disease Models, Animal; Electrodes; Electrophysiol | 1993 |
Pyridoxine as therapy in theophylline-induced seizures.
Topics: Aminophylline; Animals; Bronchodilator Agents; Disease Models, Animal; Electroencephalography; Femal | 1995 |
In vivo/in vitro studies on the effects of cyclophosphamide on growth and differentiation of hamster palate.
Topics: Animals; Collagen; Cricetinae; Cyclophosphamide; Disease Models, Animal; Drug Therapy, Combination; | 1996 |
Age-specific N-methyl-D-aspartate-induced seizures: perspectives for the West syndrome model.
Topics: Age Factors; Animals; Behavior, Animal; Disease Models, Animal; Electroencephalography; Humans; Hydr | 1999 |
Dietary vitamin B6 supplementation prevents ethanol-induced hypertension in rats.
Topics: Analysis of Variance; Animals; Blood Pressure Determination; Dietary Supplements; Disease Models, An | 1999 |
Supplementation of atherogenic diet with B vitamins does not prevent atherosclerosis or vascular dysfunction in monkeys.
Topics: Animals; Arteriosclerosis; Blood Coagulation; Carotid Arteries; Cholesterol; Diet, Atherogenic; Diet | 2001 |
Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model.
Topics: Animals; Apolipoproteins E; Arteriosclerosis; Cells, Cultured; Diet; Disease Models, Animal; Folic A | 2001 |
Pyridoxine-induced neuropathy in rats: a sensory neuropathy that responds to 4-methylcatechol.
Topics: Animals; Body Weight; Catechols; Disease Models, Animal; Electromyography; Female; Neurons, Afferent | 2001 |
Experimental model of pyridoxine (B6) deficiency-induced neuropathy.
Topics: Animals; Axons; Disease Models, Animal; Female; Gait; Nerve Fibers, Myelinated; Peripheral Nervous S | 2001 |
B vitamins induce an antinociceptive effect in the acetic acid and formaldehyde models of nociception in mice.
Topics: Acetic Acid; Animals; Constriction; Disease Models, Animal; Dose-Response Relationship, Drug; Edema; | 2001 |
In vivo gene therapy for pyridoxine-induced neuropathy by herpes simplex virus-mediated gene transfer of neurotrophin-3.
Topics: Animals; Behavior, Animal; Cells, Cultured; Disease Models, Animal; Electrophysiology; Ganglia, Spin | 2002 |
Antimicrobial therapy of vitamin B6-dependent streptococcal endocarditis.
Topics: Adult; Animals; Disease Models, Animal; Drug Synergism; Endocarditis, Bacterial; Humans; Male; Micro | 1977 |
Pargyline-induced myopathy in rats and vitamin B6.
Topics: Animals; Disease Models, Animal; Female; Magnesium; Muscles; Muscular Diseases; Pargyline; Pyridoxin | 1975 |
[Experimental pyridoxine neuropathy--an electrophysiological and histological study in rabbits].
Topics: Animals; Disease Models, Animal; Male; Peripheral Nervous System Diseases; Pyridoxine; Rabbits | 1985 |
[Liver and blood enzyme spectra of rats with model anthracosis based on feeding a diet with additional amounts of methionine and pyridoxine].
Topics: Animals; Anthracosilicosis; Dietary Fats; Disease Models, Animal; Drug Evaluation, Preclinical; Live | 1985 |
Correlation of experimental and clinical investigation of the pill.
Topics: Animals; Contraceptive Agents; Depression; Disease Models, Animal; Female; Humans; Pyridoxine | 1973 |
Serial in vivo determinations of nerve conduction velocity in rat tails. Physiological and pathological changes.
Topics: Animals; Body Temperature; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Disease Models, A | 1973 |
Experimental inhibition of serotonin by antibiotic: prevention of cerebral vasospasm.
Topics: Animals; Cerebral Angiography; Disease Models, Animal; Evaluation Studies as Topic; Haplorhini; Isch | 1974 |
Homocystinemia. Vascular injury and arterial thrombosis.
Topics: Adolescent; Adult; Animals; Blood Cell Count; Blood Coagulation; Blood Platelets; Blood Vessels; Dip | 1974 |
[Acid-base variables in the arterial blood of dogs in hypoxia treated with 2-oxo-5-hidroxy-carbonil-pentanoate of pyridoxine (author's transl)].
Topics: Acid-Base Equilibrium; Animals; Carbon Dioxide; Disease Models, Animal; Dogs; Female; Hypoxia; Injec | 1974 |
[Treatment of acute experimental lymphostatic edema with vitamins, with vitamin-like natural substances and with massage].
Topics: Animals; Ascorbic Acid; Coumarins; Disease Models, Animal; Ligation; Lymphatic Diseases; Male; Massa | 1971 |
[Kynureninase activity and pyridoxine elimination in rats with experimental phenylketonuria].
Topics: Animals; Disease Models, Animal; Humans; Hydrolases; Kynurenine; Liver; Phenylketonurias; Pyridoxine | 1971 |
[Neurotoxic side-effects of piperazine derivatives in electroencephalography. 3. Animal experimental studies on rabbits].
Topics: Animals; Brain; Disease Models, Animal; Electroencephalography; Piperazines; Pyridoxine; Rabbits; Se | 1969 |
The effect of penicillamine on seizure threshold. The role of pyridoxine.
Topics: Animals; Disease Models, Animal; Male; Myoclonus; Penicillamine; Pyridoxine; Rats; Seizures; Tryptop | 1970 |
Teratogenicity of vitamin B6 deficiency: omphalocele, skeletal and neural defects, and splenic hypoplasia.
Topics: Animals; Brain; Cleft Palate; Disease Models, Animal; Female; Hernia, Ventral; Limb Deformities, Con | 1970 |
[Influence of isoniazid (INH) on the central nervous system and the antagonism between isoniazid and pyridoxine as well as pantothenic acid and coumarin from Melilotus officinalis in rats].
Topics: Animals; Central Nervous System; Conditioning, Classical; Coumarins; Disease Models, Animal; Isoniaz | 1970 |